Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (11-20 of 350) with videos related to

Pageof 35
Sort By:
Gastroenterology|April 17, 2025
The Gravity of a Unique Subcutaneous Anti-IL23 Induction RegimenJudith Wellens, Erwin Dreesen, Marc Ferrante
Gut|September 17, 2013
Recent advances: Personalised use of current Crohn's disease therapeutic optionsSéverine Vermeire, Marc Ferrante, Paul Rutgeerts
Expert Opinion on Biological Therapy|March 5, 2013
Certolizumab pegol in the treatment of Crohn's diseaseMarc Ferrante, Séverine Vermeire, Paul Rutgeerts
Postgraduate Medical Journal|February 19, 2014
Republished: Recent advances: personalised use of current Crohn's disease therapeutic optionsSéverine Vermeire, Marc Ferrante, Paul Rutgeerts
The AAPS Journal|November 23, 2016
Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of AdalimumabSumin Bian, Marc Ferrante, Ann Gils
Current Gastroenterology Reports|September 29, 2014
The use of prognostic factors in inflammatory bowel diseasesThomas Billiet, Marc Ferrante, Gert Van Assche
Expert Opinion on Drug Safety|October 26, 2013
Drug safety evaluation of certolizumab pegolMarc Ferrante, Séverine Vermeire, Paul J Rutgeerts
Gastroenterology|September 12, 2018
Edematous Colitis of an Unknown Cause, Diagnosis by Pattern RecognitionMichiel Bronswijk, Gert De Hertogh, Marc Ferrante
Journal of Crohn'S & Colitis|December 20, 2020
Organoid-based Models to Study the Role of Host-microbiota Interactions in IBDMartina Poletti, Kaline Arnauts, Marc Ferrante, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitisYannick Hoffert, Marc Ferrante, Bram Verstockt, et al.
Pageof 35

Showing results (11-20 of 350) with videos related to

Sort By:
Pageof 35
Gastroenterology|April 17, 2025
The Gravity of a Unique Subcutaneous Anti-IL23 Induction RegimenJudith Wellens, Erwin Dreesen, Marc Ferrante
Gut|September 17, 2013
Recent advances: Personalised use of current Crohn's disease therapeutic optionsSéverine Vermeire, Marc Ferrante, Paul Rutgeerts
Expert Opinion on Biological Therapy|March 5, 2013
Certolizumab pegol in the treatment of Crohn's diseaseMarc Ferrante, Séverine Vermeire, Paul Rutgeerts
Postgraduate Medical Journal|February 19, 2014
Republished: Recent advances: personalised use of current Crohn's disease therapeutic optionsSéverine Vermeire, Marc Ferrante, Paul Rutgeerts
The AAPS Journal|November 23, 2016
Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of AdalimumabSumin Bian, Marc Ferrante, Ann Gils
Current Gastroenterology Reports|September 29, 2014
The use of prognostic factors in inflammatory bowel diseasesThomas Billiet, Marc Ferrante, Gert Van Assche
Expert Opinion on Drug Safety|October 26, 2013
Drug safety evaluation of certolizumab pegolMarc Ferrante, Séverine Vermeire, Paul J Rutgeerts
Gastroenterology|September 12, 2018
Edematous Colitis of an Unknown Cause, Diagnosis by Pattern RecognitionMichiel Bronswijk, Gert De Hertogh, Marc Ferrante
Journal of Crohn'S & Colitis|December 20, 2020
Organoid-based Models to Study the Role of Host-microbiota Interactions in IBDMartina Poletti, Kaline Arnauts, Marc Ferrante, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitisYannick Hoffert, Marc Ferrante, Bram Verstockt, et al.
Pageof 35